You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Management of Cancer Medication-Related Infusion Reactions

Version: 1 aoû 2019
Type of Content: Guidelines & Advice
Document Status: Current
Authors:
Andrea Crespo, Leta Forbes, Daniela Gallo-Hershberg, Katherine Enright, Vishal Kukreti, Lorraine Martelli, Carlo DeAngelis, Anna Granic, Leonard Kaizer, Melissa Lot, Charmaine Mothersill, Ferid Rashid, Lily Spasic, Leslie Young, Jason Yu

Guideline Objective

The objective of this guideline is to facilitate a standardized approach to cancer medication-related infusion reactions in Ontario. The guideline is informed by best available evidence and expert consensus, and provides recommendations on assessment, prophylaxis, acute management, and re-challenge (including desensitization). Supporting resources for healthcare providers include an acute management algorithm, a drug table, and a desensitization protocol calculation tool. A patient-information sheet has been developed based on health literacy best practices and patient and caregiver input.

Patient Population

Adult patients receiving systemic treatment.

Intended Guideline Users

Clinicians involved in the care of patients receiving systemic treatment (Physicians, Pharmacists, Nurses)

Research Questions

N/A

pdf download Full Report (PDF) (803.78 Ko)